Fig. 4: Gene expression profiling of bulk CD93-selected CP-CML LSCs confirms their quiescent character. | Leukemia

Fig. 4: Gene expression profiling of bulk CD93-selected CP-CML LSCs confirms their quiescent character.

From: CD93 is expressed on chronic myeloid leukemia stem cells and identifies a quiescent population which persists after tyrosine kinase inhibitor therapy

Fig. 4

a Schematic diagram of CD93 expression within a stem cell population. b CD93 gene expression as determined in the linCD34+CD38CD90+CD93+ and linCD34+CD38CD90+CD93 population (p = 0.0068). Results are presented as fold change compared with the CD34+ bulk population using the ΔΔCt method. c Key genes involved in lineage restriction were overexpressed in the linCD34+CD38CD90+CD93 population, namely GATA1 and CBX8. d Key genes involved in stem cell maintenance were upregulated in the linCD34+CD38CD90+CD93+ population. e Normalized differential gene expression of the single cells using the ΔΔCt method. The control sample is the mean of the CD93 on each chip. GATA1 was significantly downregulated in the CD93+ population (n = 2 CP-CML samples, q = 0.03). f Principal component analysis (PCA) of the four different populations defined by CD93 surface presence and BCR-ABL1 expression. Each individual dot represents a single cell. It can be observed that the CD93+ BCR-ABL1+ cells (in red) are more heterogeneous than the other populations and that they form a slightly different cluster.

Back to article page